Edwards Lifesciences (EW) Cash & Equivalents (2009 - 2026)

Edwards Lifesciences' Cash & Equivalents history runs 18 years deep, the most recent figure standing at $2.4 billion for Q1 2026.

• On a quarterly basis, Cash & Equivalents fell 22.13% year-over-year to $2.4 billion in Q1 2026; TTM through Mar 2026 was $2.4 billion, a 22.13% decrease from a year earlier, with the FY2025 full-year figure at $2.9 billion, down 3.52% from the prior year.
• Cash & Equivalents fell to $2.4 billion in Q1 2026 per EW's latest filing, from $2.9 billion in the prior quarter.
• Across five years, Cash & Equivalents topped out at $3.7 billion in Q3 2024 and bottomed at $11.7 million in Q4 2023.
• The 5-year median for Cash & Equivalents is $1.4 billion (2023), against an average of $1.9 billion.
• Across the five-year window, Cash & Equivalents tumbled 98.46% in 2023 and surged 25927.35% in 2024, its largest moves.
• Year by year, Cash & Equivalents stood at $761.5 million in 2022, then tumbled by 98.46% to $11.7 million in 2023, then jumped by 25927.35% to $3.0 billion in 2024, then decreased by 3.52% to $2.9 billion in 2025, then dropped by 16.76% to $2.4 billion in 2026.
• Per Business Quant, the three latest EW Cash & Equivalents figures stand at $2.4 billion (Q1 2026), $2.9 billion (Q4 2025), and $2.7 billion (Q3 2025).